CI

At a glance

ClinicalIndex Comparison Record
Phase 2Not Yet Recruiting· 108 target
Drug / intervention
LM-168 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07669415
NCT07669415Phase 2Not Yet Recruiting
CompareCT.gov

A Phase II，Open Label,Multicenter Study to Evaluate the Efficacy,Safety,and Tolerability of LM-168 Combined With Other Anti-tumor Therapies in Participants With Advanced Solid Tumor Trials

LaNova Medicines Limited·interventional·Posted Jun 25, 2026·Updated Jun 25, 2026

In Brief

A Phase 2 clinical trial evaluating LM-168, Tislelizumab, and 1 other intervention for Advanced Solid Tumor. Not yet recruiting, targeting 108 participants across 1 site.

Detailed Summary

For Safety introduction phase，this study is to evaluate the safety and tolerability of LM-168 in combination with other anti-tumor treatment regimens in participants of advanced solid tumor trials, determine the maximum tolerated dose (MTD), and explore the recommended phase II dose (RP2D). For Dose expansion phase，this study is to evaluate the preliminary antitumor activity of LM-168 in combination with other antitumor treatment regimens in participants of advanced solid tumor trials, measured by objective response rate (ORR)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--

Timeline

Phase 2Not Yet Recruiting
202720282029
First PostedJun 25, 2026
Enrollment StartJun 30, 2026
Primary CompletionDec 15, 2027
Study CompletionDec 15, 2028
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 6 days agoPrimary completion in 1.5 years

Arms & Interventions

LM-168 + Tislelizumab Safety introductionexperimental

Drug: LM-168Drug: Tislelizumab
LM-168 Dose Expansionexperimental

Drug: LM-168
LM-168 + Tislelizumab Dose Expansionexperimental

Drug: LM-168Drug: Tislelizumab
LM-168 + Tislelizumab +Other anti-tumor treatments Dose Expansionexperimental

Drug: LM-168Drug: TislelizumabDrug: Docetaxel injection

Interventions

LM-168drug

Q3W,Intravenous Drip

Tislelizumabdrug

Q3W,Intravenous Drip

Docetaxel injectiondrug

Q3W,Intravenous Drip